VIA
CYTK icon

Vantage Investment Advisors’s Cytokinetics CYTK Stock Holding History

Vantage Investment Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,000
Closed -$7K – 788
2015
Q2 		$7K Hold
1,000
– – ﹤0.01% 553
2015
Q1 		$7K Buy
+1,000
New +$7.47K ﹤0.01% 654

Other funds holding CYTK

LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Vantage Investment Advisors's CYTK Position: Q3 2015 in Review

Vantage Investment Advisors sold out of Cytokinetics (CYTK) in Q3 2015, closing a stake of 1,000 shares — an estimated $7K sold.

Vantage Investment Advisors first reported a position in CYTK in Q1 2015 and held it in 2 quarters. The position peaked at $7K in Q2 2015. 105 funds tracked by Wall St. Rank hold CYTK as of Q3 2015.

  • Vantage Investment Advisors reported no remaining Cytokinetics position as of Q3 2015 after selling out during the quarter.
  • Vantage Investment Advisors sold 1,000 Cytokinetics shares in Q3 2015, an estimated $7K.
  • Vantage Investment Advisors first reported a position in Cytokinetics in Q1 2015 and held it in 2 quarters.
  • Vantage Investment Advisors's Cytokinetics position peaked at $7K in Q2 2015.
  • 105 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2015.

Based on Vantage Investment Advisors's 13F filing for Q3 2015, filed 16 Nov 2015.